Reduced Cross-Sectional Muscle Growth Six Months after Botulinum Toxin Type-A Injection in Children with Spastic Cerebral Palsy

Botulinum Neurotoxin type-A (BoNT-A) injections are widely used as first-line spasticity treatment in spastic cerebral palsy (SCP). Despite improved clinical outcomes, concerns regarding harmful effects on muscle morphology have been raised. Yet, the risk of initiating BoNT-A to reduce muscle growth...

Descripción completa

Detalles Bibliográficos
Autores principales: De Beukelaer, Nathalie, Weide, Guido, Huyghe, Ester, Vandekerckhove, Ines, Hanssen, Britta, Peeters, Nicky, Uytterhoeven, Julie, Deschrevel, Jorieke, Maes, Karen, Corvelyn, Marlies, Costamagna, Domiziana, Gayan-Ramirez, Ghislaine, Van Campenhout, Anja, Desloovere, Kaat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876834/
https://www.ncbi.nlm.nih.gov/pubmed/35202166
http://dx.doi.org/10.3390/toxins14020139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876834/
https://www.ncbi.nlm.nih.gov/pubmed/35202166
http://dx.doi.org/10.3390/toxins14020139

Ejemplares similares